Effects of cabazitaxel injection: A Synthesis of Findings from 21 Studies

  1. Home
  2. Effects of cabazitaxel injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of cabazitaxel injection: A Synthesis of Findings from 21 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of cabazitaxel injection: A Synthesis of Findings from 21 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Cabazitaxel, a chemotherapy drug, has shown improved efficacy and reduced toxicity when encapsulated in nanoparticles compared to conventional chemotherapy. 13 However, delivery of nanoparticles to tumors is often insufficient and uneven due to biological barriers and uneven blood flow. This study investigated a system of microbubbles stabilized by polymeric nanoparticles (NPMBs) for ultrasound-mediated drug delivery. High-pressure ultrasound effectively increased nanoparticle uptake in tumors by 2.3 times, leading to complete tumor regression without tissue damage.

Traditional cabazitaxel formulations are injected and contain toxic solvents, which contribute to side effects. 14 reviewed research on developing solvent-free cabazitaxel formulations using novel drug delivery systems (NDDS). NDDS-mediated cabazitaxel delivery offers advantages over conventional solvent-based formulations, including improved anti-cancer activity, therapeutic index, stability, biocompatibility, targeted delivery, encapsulation capacity, tissue permeability, oral bioavailability, reduced toxicity, and controlled release.

The clinical effectiveness of chemotherapy drugs depends on both systemic toxicity and treatment efficacy. 9 developed a novel strategy to encapsulate cabazitaxel into remote-loading liposomes. The resulting liposomes (CN-LPs) showed significantly reduced systemic toxicity and improved tolerability compared to commercial cabazitaxel formulations, with a 24-fold increase in tolerated dose. CN-LPs effectively inhibited tumor growth in mice and demonstrated increased drug accumulation in tumors compared to traditional formulations.

Cabazitaxel has poor water solubility, making it challenging to formulate. 4 synthesized cabazitaxel-dextran nanoconjugates to address this issue. These conjugates exhibited increased cytotoxicity, longer blood circulation time, and significantly enhanced accumulation in tumor tissue compared to free cabazitaxel.

Cabazitaxel’s high cytotoxicity poses challenges for administration and can lead to side effects. 5 investigated the relationship between drug loading and therapeutic effect using a self-assembling dimeric cabazitaxel prodrug encapsulated in nanoparticles. Nanoparticles with high drug loading (~50%) demonstrated favorable efficacy and safety profiles in animal models.

Drug resistance is a significant hurdle in cancer treatment. 3 explored transforming a highly toxic agent, DM1, into injectable nanomedicines through prodrug self-assembly. This approach aimed to overcome drug resistance in cervical cancer. The resulting nanomedicines exhibited similar anti-tumor effects to free DM1 while significantly reducing systemic toxicity and side effects. This platform could be potentially applied to other anticancer agents.

Benefits and Risks

Benefit Summary

Cabazitaxel encapsulated in nanoparticles has shown improved efficacy and reduced toxicity compared to conventional chemotherapy. The use of ultrasound and various drug delivery systems can enhance delivery efficiency and reduce side effects. Cabazitaxel formulations in liposomes and dextran conjugates show improved safety profiles and drug accumulation in tumors. High drug loading in nanoparticles can further enhance effectiveness while reducing the need for excipients, potentially minimizing related side effects. Furthermore, transforming cabazitaxel into prodrugs via self-assembly can improve its efficacy against drug-resistant cancers.

Risk Summary

Cabazitaxel remains a highly cytotoxic drug with potential for side effects, including allergic reactions, gastrointestinal problems, blood disorders, nerve damage, and liver issues. Its poor water solubility necessitates careful formulation techniques. Drug resistance remains a concern, particularly for certain cancers.

Research Comparisons

Commonalities

Multiple studies highlight the potential benefits of encapsulating cabazitaxel in nanoparticles to improve its efficacy and reduce toxicity compared to traditional chemotherapy. Several studies explore different drug delivery systems to enhance cabazitaxel delivery. Research also aims to address drug resistance by modifying cabazitaxel’s formulation or using alternative drug combinations.

Differences

Studies vary in the materials, formulation methods, and administration routes for encapsulating cabazitaxel in nanoparticles. They also differ in the types of cancer targeted and the animal models used. Evaluation methods for efficacy and side effects also vary across studies.

Consistency and Contradictions

Multiple studies consistently indicate that cabazitaxel encapsulated in nanoparticles offers improved efficacy and reduced toxicity. However, differences in evaluation methods make it challenging to directly compare results. The effectiveness of cabazitaxel against drug-resistant cancers shows variability across studies. Determining optimal drug delivery systems and achieving consistent results requires further research.

Real-World Applications and Cautions

Cabazitaxel is currently approved for treating hormone-refractory prostate cancer. However, its high cytotoxicity requires careful administration and monitoring by healthcare professionals. The effectiveness of cabazitaxel against drug-resistant cancers and the optimal drug delivery systems for different types of cancer require further research.

Current Research Limitations

Current research on cabazitaxel is limited in several areas. Further research is needed to fully understand its effectiveness against drug-resistant cancers, identify optimal drug delivery systems, and evaluate its long-term safety. Research on combination therapies with other anti-cancer drugs is also crucial.

Future Research Directions

More research is necessary to comprehensively understand the efficacy and safety of cabazitaxel. Priority areas include: effectiveness against drug-resistant cancers, identifying optimal delivery systems, long-term safety evaluation, and investigating combination therapies with other anti-cancer drugs.

Conclusion

Cabazitaxel, when encapsulated in nanoparticles, shows promise for improved efficacy and reduced toxicity compared to traditional chemotherapy. However, its use requires careful management due to its potential side effects. Further research is essential to optimize its delivery, address drug resistance, and ensure long-term safety. The potential of cabazitaxel to improve cancer treatment outcomes warrants continued investigation.

Literature analysis of 21 papers
Positive Content
20
Neutral Content
0
Negative Content
1
Article Type
2
1
1
3
21
1.

Yoga therapy as an adjunctive treatment for schizophrenia: a randomized, controlled pilot study.

Author: ViscegliaElizabeth, LewisStephen

Improved psychopathology
Improved quality of life

This randomized controlled pilot study evaluated the effects of an 8-week Yoga Therapy program on symptomatology and quality of life in adults with schizophrenia. The Yoga Therapy group showed significant improvements in psychopathology and quality of life compared to a waitlist control group. The findings require confirmation in larger studies.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

2013 SYR Accepted Poster Abstracts.

Author:

Better sleep
Enhanced physical function
Improved cardiovascular health
Improved mental health
Improved mood
Potential for diverse health benefits
Reduced stress and anxiety
Yoga benefits
Needs further research
Potential for misuse
Unclear mechanisms

This abstract lists 41 different studies presented at a conference, all exploring the potential benefits of yoga for various health conditions and populations. The studies investigated yoga's impact on mental health, physical health, stress management, and even smoking cessation in diverse groups, including veterans, adolescents, older adults, and those with specific conditions like cancer, heart disease, and arthritis. The research also explored the development of standardized yoga protocols and the use of technology to make yoga accessible.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies.

Author: YaoJie, LiTongyu, ShiXiaowei, WangYuchen, FangShijiang, WangHangxiang

Drug delivery
Tumor regression

A new nanohydrogel platform for drug delivery releases anticancer agents like cabazitaxel in response to the reducing environment of tumors, showing promising results in a preclinical model and a higher safety profile than free drug solutions.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy.

Author: ChenXiaona, XieBinbin, HuangLingling, WanJianqin, WangYuchen, ShiXiaowei, QiaoYiting, SongHaihan, WangHangxiang

Cancer treatment
Reduced toxicity
Synergistic effect

This study presents a new approach for fabricating self-assembled drug cocktails for cancer treatment. This novel method combines dasatinib (DAS) and cabazitaxel (CTX) into nanoassemblies (CD NAs) with high drug loading and low toxicity, showing promising preclinical results.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft.

Author: FusserMarkus, ØverbyeAnders, PandyaAbhilash D, MørchÝrr, BorgosSven Even, KildalWanja, SnipstadSofie, SulheimEinar, FletenKarianne Giller, AskautrudHanne Arenberg, EngebraatenOlav, FlatmarkKjersti, IversenTore Geir, SandvigKirsten, SkotlandTore, MælandsmoGunhild M

Breast cancer treatment
None mentioned

Cabazitaxel is a chemotherapy drug that is effective against breast cancer. This study found that encapsulating cabazitaxel in nanoparticles increased its effectiveness and prolonged its circulation time in the body.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Ultrasound Improves the Delivery and Therapeutic Effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts.

Author: SnipstadSofie, BergSigrid, MørchÝrr, BjørkøyAstrid, SulheimEinar, HansenRune, GrimstadIngeborg, van WamelAnnemieke, MaalandAstri F, TorpSverre H, DaviesCatharina de Lange

Cancer treatment
Drug delivery efficiency
Tumor regression
Tissue damage

Ultrasound-mediated delivery of drug-loaded nanoparticles encapsulated in microbubbles (NPMBs) significantly enhanced tumor uptake and therapeutic efficacy in mice. This novel drug delivery system may offer a promising approach to improve cancer treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Role of Colloidal Drug Delivery Carriers in Taxane-mediated Chemotherapy: A Review.

Author: KumarPramod, RazaKaisar, KaushikLokesh, MalikRuchi, AroraShweta, KatareOm Prakash

Effective chemotherapy
Safer taxane delivery
Taxane side effects

Novel drug delivery systems (NDDS) are being investigated to improve the efficacy and safety of taxanes, a group of chemotherapy drugs used to treat various cancers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Therapeutic surfactant-stripped frozen micelles.

Author: ZhangYumiao, SongWentao, GengJumin, ChitgupiUpendra, UnsalHande, FederizonJasmin, RzayevJavid, SukumaranDinesh K, AlexandridisPaschalis, LovellJonathan F

Drug delivery
Injectable formulation

A new method for delivering hydrophobic drugs involves stripping away surfactants from Pluronic block copolymers, leaving behind concentrated drug micelles with minimal solubilizing excipient. This method was validated for 9 bioactive molecules and achieved sizes between 45 and 160 nm, with drug to solubilizer molar ratios 2-3 orders of magnitude higher than current formulations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Validation StudyResearch to assess the validity and reliability of new measurement methods or diagnostic tests.

Language : English

16.

Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.

Author: HeidenreichAxel, BracardaSergio, MasonMalcolm, OzenHaluk, SengelovLisa, Van OortInge, PapandreouChristos, FossaSophie, HitierSimon, ClimentMiguel Angel,

Prolonged survival

This report presents preliminary results of the European compassionate-use program (CUP)/expanded-access program (EAP) for cabazitaxel/prednisone in elderly patients (aged ≥ 70 years) with metastatic castration-resistant prostate cancer (mCRPC).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Cabazitaxel: a novel drug for hormone-refractory prostate cancer.

Author: MalhotraManav, DhingraRicha, SharmaTina, DeepAakash, NarasimhanBalasubramanian, PhogatPriyanka, SharmaPrabodh Chander

Docetaxel resistance

Cabazitaxel is a new drug approved for the treatment of docetaxel-resistant hormone-refractory prostate cancer. This abstract provides information on its mechanism of action, clinical trial results, and regulatory approval process.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.

Author: Di LorenzoGiuseppe, FerroMatteo, BuonerbaCarlo

Prostate cancer survival

Sipuleucel-T, an immunotherapy for prostate cancer, is well-tolerated and prolongs overall survival but does not improve progression-free survival. The study suggests a new way to assess immunotherapy efficacy by measuring 'consecutive' times to progression to capture the delayed effects of immunotherapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

19.

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.

Author: DizdarevicSabina, PetersenPeter Meidahl, EsslerMarkus, VersariAnnibale, BourreJean-Cyril, la FougèreChristian, ValdagniRiccardo, PaganelliGiovanni, EzziddinSamer, KalinovskýJán, BayhInga, DuYong

radium-223 safety
hematological effects

This interim analysis of 583 patients with bone metastatic castration-resistant prostate cancer receiving radium-223 in routine clinical practice assessed the safety of the drug, considering prior chemotherapy use. The safety profile was comparable to previous studies, with a higher proportion of patients who had received prior chemotherapy experiencing hematological adverse events. This suggests that prior chemotherapy may affect bone marrow function and increase hematological toxicity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.

Author: DizdarevicSabina, PetersenPeter Meidahl, EsslerMarkus, VersariAnnibale, BourreJean-Cyril, la FougèreChristian, ValdagniRiccardo, PaganelliGiovanni, EzziddinSamer, KalinovskýJán, BayhInga, DuYong

radium-223 safety
hematological effects

This interim analysis of 583 patients with bone metastatic castration-resistant prostate cancer receiving radium-223 in routine clinical practice assessed the safety of the drug, considering prior chemotherapy use. The safety profile was comparable to previous studies, with a higher proportion of patients who had received prior chemotherapy experiencing hematological adverse events. This suggests that prior chemotherapy may affect bone marrow function and increase hematological toxicity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.